Natera Enters Into Partnership With The Feinstein Institute For Medical Research To Advance Cancer Diagnostics Research

SAN CARLOS, Calif. & MANHASSET, N.Y.--(BUSINESS WIRE)--Natera, Inc., a leader in non-invasive genetic testing, and the Feinstein Institute for Medical Research today announced that they have entered into a research agreement to analyze cell-free circulating tumor DNA (ctDNA) for advanced detection, diagnosis and monitoring of cancer. Under the terms of the agreement, Natera will provide funding to the Feinstein Institute, which will contribute blood and tissue samples to Natera for the development of technology that can detect tiny fragments of tumor DNA in a patient’s bloodstream.

Help employers find you! Check out all the jobs and post your resume.